An overview is given of the in vitro test results on MCF-7, a mammary tumour, and WiDr, a colon carcinoma, of several series of organotin compounds synthesized in the Free University of Brussels VUB. Several compounds exhibit a very promising antitumour activity.
The di-n-butyltin compounds are again the most active ones. For instance, di-n-butyltin bis (4-hydroxy-3-methoxybenzoate) is characterized by ID 50 values of 44 and 82 ng/mL against and WiDr, respectively^2).
Antitumour activity of bis[carboxylato(diorganotin)] oxides
When a 1:1 molar ratio is used, a dimer of a bis[carboxylato(diorganotin)] oxide is obtained. The structure of [diethyl (2-methylthio-3-pyridinecarboxylato) Here again, the di-n-butyltin compounds proved to be the most active ones, much more active than cisplatin: the 1:1 condensation compound di-n-butyltin oxide and 5-methoxysalicylic acid, { 
Condensation complex of di-n-butyltin oxide with salicylaldoxime
Whereas di-n-butyltin oxide and carboxylic acids react either in a 1:1 or 1:2 molar ratio, the condensation complex of di-n-butyltin oxide with salicylaldoxime gives, after recrystallization, always a 3:2 derivative, compound M, independently from the molar ratio used. The molecular structure of compound Μ in the crystalline state is shown belowW. Vol. 17, Νos. 1-4, 1994 Tin-Based Antitumour Drug* Inhibition doses ID 50 of 67 and 215 ng/mL are found against MCF-7 and WiDr respectively for compound M, that was also tested by the NCI against a panel of 60 human tumour cell lines( 5 ).
M:
chemistry ( 4 ). Indeed, when Μ is dissolved in chloroform or in benzene, it maintains its solid state structure, as shown by multinuclear 1D NMR and by 2D NMR techniques^4). However, three new compounds are formed in solution from Μ as minor species, viz. ml, m2 and m3. The following structures have been proposed for these three new complexes on the basis of NMR and of chemical evidence^4).
Μ. Gielen Main Group Metal Chemistry
Compound ml is quite similar to Μ but contains one more salicylaldoximate moiety coordinated to the two five-coordinate tin atoms.
Compound m2 contains two equivalent six-coordinate and two equivalent five-coordinate tin atoms and two equivalent salicylaldoximate ligands.
m2:
R R R R Compound m3 has got four equivalent tin atoms, one of each being coupled to its three neighbours, with an adamantane-based Sn 4 0 6 cluster structure, two of the oxygen atoms originating from two distannoxane moieties and the four other ones, from the four equivalent salicylaldoximate ligands.
m3:
When this equilibrium mixture at room temperature is kept up for a certain time at higher temperatures, the ratio of the four components determined by NMR for that new solution at room temperature changes: Μ decreases, ml and m2 increase and m3 disappears. After a long time at room temperature, the initial composition is again reached showing that M, ml, m2 and m3 are indeed in equilibrium in chloroform or benzene solution. It should be underlined that the addition of water to the equilibrium mixture converts ml, m2 and m3 back into M. Because the in vitro tests are performed with diluted water solutions, it is obvious that the antitumour activity of Μ has been determined.
Antitumour activity of diorganostannates
In order to increase the water-solubility of these diorganotin derivatives, which might be a way to increase the antitumour activity, following AtassK 6 ), we converted them ( 7 ) into their tetraethylammonium halide adducts.
The in vitro antitumour activity of the tetraethylammonium halide adducts of the diorganotin 2,6-pyridine dicarboxylates ( 7 ) is not better than that of the parent molecules, even if their solubility in 6 protic and also in less polar solvents is considerably enhanced.
Exceptionally high antitumour activity of triphenyltin carboxylates
We prepared several series of organotin molecules that are as active in vitro as mitomycin C against MCF-7 and WiDr. The first of these, that have recently been patented^1), are triphenyltin
carboxylates ( We have even prepared other series of organotin compounds that were found more active than these last ones but that have first to be patented before more can be told about them.
Conclusion
Many di-and triorganotin compounds have been found much more active than cis-platin in vitro against two human tumour cell lines, MCF-7, a mammary tumour, and WiDr, a colon carcinoma. Of course one has to wait for the in vivo test results before claiming anything about the real interest of such compounds in the field of cancer chemotherapy: more work has indeed to be done in order to find organotin molecules that might become useful antitumour drugs in the future.
